Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Sep 3;383(10):986-989.
doi: 10.1056/NEJMc2001362.

Janus Kinase Inhibition in the Aicardi-Goutières Syndrome

Adeline Vanderver  1 , Laura Adang  1 , Francesco Gavazzi  1 , Katherine McDonald  1 , Guy Helman  2 , David B Frank  3 , Nicole Jaffe  3 , Sabrina W Yum  3 , Abigail Collins  4 , Stephanie R Keller  5 , Pierre Lebon  6 , Jean-François Meritet  7 , Jullie Rhee  8 , Asako Takanohashi  3 , Thais Armangue  9 , Nicole Ulrick  3 , Omar Sherbini  3 , Jamie Koh  3 , Kyle Peer  3 , Constance Besnier  3 , Carly Scher  3 , Katherine Boyle  3 , Holly Dubbs  3 , Julia Kramer-Golinkoff  3 , Amy Pizzino  3 , Sarah Woidill  3 , Justine Shults  10
Affiliations
Clinical Trial

Janus Kinase Inhibition in the Aicardi-Goutières Syndrome

Adeline Vanderver et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Changes in Symptoms, Interferon Gene Expression, and Developmental Skills in Children with the Aicardi–Goutières Syndrome.
As shown in Panel A, a decrease in symptoms during the study was indicated by reduced skin inflammation in the neck, face, toes, and hands of the patients. In Patient 1, the findings shown are from 3 days after the initiation of treatment; in Patient 2, from 1 month after the initiation of treatment; and in Patient 3, from the 18-month visit (the clinical cutoff date for data analysis). As shown in Panel B, the interferon-signaling gene (ISG) expression scores decreased during treatment. This score is calculated from the expression of six interferon-signaling genes normalized to housekeeping genes. The six-gene interferon signature is the sum of the median z scores of these genes. The interferon signature is positive (i.e., type 1 interferon signaling is high) if it is at least 1.96 (>98th percentile) on a one-tailed test (see Section 3.1.6 in the Supplementary Appendix). As shown in Panel C, symptom scores recorded in diaries by the patients’ parents decreased during treatment. Recorded symptoms were neurologic disability, crying, sleep disturbances, irritability, seizures, fever, and skin inflammation of the trunk, arms, and legs (see the Supplemental Methods section and Table S5 in the Supplementary Appendix). As shown in Panel D, developmental milestones in the individual patients were met during treatment. Each bar represents an individual patient. As shown in Panel E, the gain of new milestones correlated with the dose of baricitinib. Target doses varied according to weight-based norms (see the Supplementary Methods section in the Supplementary Appendix). In Panels B, C, and E, each circle represents an individual patient. Horizontal lines indicate means, and I bars standard deviations.
See this image and copyright information in PMC

Comment in

  • JAK Inhibition in the Aicardi-Goutières Syndrome.
    Neven B, Al Adba B, Hully M, Desguerre I, Pressiat C, Boddaert N, Duffy D, Rice GI, Seabra L, Frémond ML, Blanche S, Crow YJ. Neven B, et al. N Engl J Med. 2020 Nov 26;383(22):2190-2191. doi: 10.1056/NEJMc2031081. N Engl J Med. 2020. PMID: 33252884 No abstract available.

Similar articles

  • Reverse-Transcriptase Inhibitors in the Aicardi–Goutières Syndrome.
    Rice GI, Meyzer C, Bouazza N, Hully M, Boddaert N, Semeraro M, Zeef LAH, Rozenberg F, Bondet V, Duffy D, Llibre A, Baek J, Sambe MN, Henry E, Jolaine V, Barnerias C, Barth M, Belot A, Cances C, Debray FG, Doummar D, Frémond ML, Kitabayashi N, Lepelley A, Levrat V, Melki I, Meyer P, Nougues MC, Renaldo F, Rodero MP, Rodriguez D, Roubertie A, Seabra L, Uggenti C, Abdoul H, Treluyer JM, Desguerre I, Blanche S, Crow YJ. Rice GI, et al. N Engl J Med. 2018 Dec 6;379(23):2275-7. doi: 10.1056/NEJMc1810983. N Engl J Med. 2018. PMID: 30566312 No abstract available.
  • Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutières Syndrome, a Type I Interferonopathy.
    Meesilpavikkai K, Dik WA, Schrijver B, van Helden-Meeuwsen CG, Versnel MA, van Hagen PM, Bijlsma EK, Ruivenkamp CAL, Oele MJ, Dalm VASH. Meesilpavikkai K, et al. Arthritis Rheumatol. 2019 May;71(5):829-831. doi: 10.1002/art.40805. Epub 2019 Mar 6. Arthritis Rheumatol. 2019. PMID: 30666809 Free PMC article. No abstract available.
  • JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R. Sanchez GAM, et al. J Clin Invest. 2018 Jul 2;128(7):3041-3052. doi: 10.1172/JCI98814. Epub 2018 Jun 11. J Clin Invest. 2018. PMID: 29649002 Free PMC article.
  • Novel and emerging treatments for Aicardi-Goutières syndrome.
    Tonduti D, Fazzi E, Badolato R, Orcesi S. Tonduti D, et al. Expert Rev Clin Immunol. 2020 Feb;16(2):189-198. doi: 10.1080/1744666X.2019.1707663. Epub 2020 Jan 6. Expert Rev Clin Immunol. 2020. PMID: 31855085 Review.
  • [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M, Mikkelsen C, Eggertsen PP, Stern M, van de Looij A, Deleuran B. Frøling M, et al. Ugeskr Laeger. 2017 Oct 30;179(44):V05170383. Ugeskr Laeger. 2017. PMID: 29084618 Review. Danish.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rice G, Patrick T, Parmar R, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 2007;81:713–25. - PMC - PubMed
    1. Briand C, Frémond M-L, Bessis D, et al. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Ann Rheum Dis 2019;78:431–3. - PubMed
    1. Kothur K, Bandodkar S, Chu S, et al. An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation. Neurology 2018;90:289–91. - PubMed
    1. Montealegre Sanchez GA, Reinhardt A, Ramsey S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 2018;128:3041–52. - PMC - PubMed
    1. Adang LA, Frank DB, Gilani A, et al. Aicardi Goutières syndrome is associated with pulmonary hypertension. Mol Genet Metab 2018;125:351–8. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts